AR125259A1 - Unidades de unión multiespecíficas que comprenden dominios de unión a pd-1 - Google Patents
Unidades de unión multiespecíficas que comprenden dominios de unión a pd-1Info
- Publication number
- AR125259A1 AR125259A1 ARP220100790A ARP220100790A AR125259A1 AR 125259 A1 AR125259 A1 AR 125259A1 AR P220100790 A ARP220100790 A AR P220100790A AR P220100790 A ARP220100790 A AR P220100790A AR 125259 A1 AR125259 A1 AR 125259A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding
- multispecific
- units
- binding domain
- novel
- Prior art date
Links
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 2
- 102000017578 LAG3 Human genes 0.000 abstract 2
- 101150030213 Lag3 gene Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000048362 human PDCD1 Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Unidades de unión multiespecíficas que comprenden nuevos dominios de unión a PD-1 que tienen una mayor afinidad de unión por la PD-1 humana que un dominio de unión a PD-1 de referencia. Dichas unidades de unión multiespecíficas proveen además una potencia comparable, o igual o mayor, para bloquear la unión a ligando a la PD-1 humana que un anticuerpo anti-PD-1 de referencia. La presente divulgación se relaciona en particular con unidades de unión multiespecíficas que comprenden un nuevo dominio de unión a PD-1 y un dominio de unión a LAG-3. También se provee un método para el tratamiento de una enfermedad, en particular una enfermedad asociada con un sistema inmunológico suprimido, tal como el cáncer, con una unidad de unión multiespecífica de la presente divulgación. La presente se relaciona además con un vector y una célula que comprenden ácidos nucleicos que codifican un nuevo dominio de unión a PD-1 y un dominio de unión a LAG-3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2027893 | 2021-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125259A1 true AR125259A1 (es) | 2023-06-28 |
Family
ID=76035096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100790A AR125259A1 (es) | 2021-03-31 | 2022-03-31 | Unidades de unión multiespecíficas que comprenden dominios de unión a pd-1 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220363761A1 (es) |
| EP (1) | EP4313311A1 (es) |
| JP (1) | JP2024512905A (es) |
| KR (1) | KR20230163504A (es) |
| CN (2) | CN117177994A (es) |
| AR (1) | AR125259A1 (es) |
| AU (1) | AU2022246842A1 (es) |
| BR (1) | BR112023019703A2 (es) |
| CA (1) | CA3213682A1 (es) |
| CL (1) | CL2023002929A1 (es) |
| CO (1) | CO2023012824A2 (es) |
| CR (1) | CR20230462A (es) |
| DO (1) | DOP2023000207A (es) |
| EC (1) | ECSP23074478A (es) |
| IL (1) | IL305600A (es) |
| MX (1) | MX2023011662A (es) |
| PE (1) | PE20240823A1 (es) |
| TW (1) | TW202304976A (es) |
| WO (1) | WO2022212516A1 (es) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US8089340B2 (en) * | 2007-01-05 | 2012-01-03 | Honeywell International Inc. | Real-time screening interface for a vehicle screening system |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| KR20180069070A (ko) * | 2015-11-03 | 2018-06-22 | 얀센 바이오테크 인코포레이티드 | Tim-3과 특이적으로 결합하는 항체 및 그의 용도 |
| US20200079850A1 (en) * | 2017-05-24 | 2020-03-12 | Sutro Biopharma, Inc. | Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same |
| CN118027197A (zh) | 2017-07-06 | 2024-05-14 | 美勒斯公司 | 调节由细胞表达的生物活性的抗体 |
| WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| GB201802573D0 (en) * | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| CN112236456B (zh) * | 2018-03-20 | 2023-12-22 | 上海药明生物技术有限公司 | 新型双特异性pd-1/lag-3抗体分子 |
| BR112020022371A2 (pt) * | 2018-05-03 | 2021-02-02 | Shanghai Epimab Biotherapeutics Co., Ltd. | anticorpos de alta afinidade para pd-1 e lag-3 e proteínas de ligação biespecífica produzidas a partir dos mesmos |
-
2022
- 2022-03-30 WO PCT/US2022/022564 patent/WO2022212516A1/en active Application Filing
- 2022-03-30 MX MX2023011662A patent/MX2023011662A/es unknown
- 2022-03-30 PE PE2023002762A patent/PE20240823A1/es unknown
- 2022-03-30 CA CA3213682A patent/CA3213682A1/en active Pending
- 2022-03-30 CN CN202280026554.1A patent/CN117177994A/zh active Pending
- 2022-03-30 IL IL305600A patent/IL305600A/en unknown
- 2022-03-30 AU AU2022246842A patent/AU2022246842A1/en active Pending
- 2022-03-30 JP JP2023553659A patent/JP2024512905A/ja active Pending
- 2022-03-30 KR KR1020237037166A patent/KR20230163504A/ko unknown
- 2022-03-30 CN CN202410351668.4A patent/CN118165109A/zh active Pending
- 2022-03-30 EP EP22717998.3A patent/EP4313311A1/en active Pending
- 2022-03-30 CR CR20230462A patent/CR20230462A/es unknown
- 2022-03-30 BR BR112023019703A patent/BR112023019703A2/pt unknown
- 2022-03-30 US US17/708,901 patent/US20220363761A1/en active Pending
- 2022-03-31 TW TW111112664A patent/TW202304976A/zh unknown
- 2022-03-31 AR ARP220100790A patent/AR125259A1/es unknown
-
2023
- 2023-09-27 CO CONC2023/0012824A patent/CO2023012824A2/es unknown
- 2023-09-28 DO DO2023000207A patent/DOP2023000207A/es unknown
- 2023-09-29 CL CL2023002929A patent/CL2023002929A1/es unknown
- 2023-09-29 EC ECSENADI202374478A patent/ECSP23074478A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023002929A1 (es) | 2024-02-16 |
| JP2024512905A (ja) | 2024-03-21 |
| TW202304976A (zh) | 2023-02-01 |
| CR20230462A (es) | 2023-11-30 |
| CO2023012824A2 (es) | 2024-01-25 |
| ECSP23074478A (es) | 2023-11-30 |
| BR112023019703A2 (pt) | 2023-10-31 |
| WO2022212516A1 (en) | 2022-10-06 |
| KR20230163504A (ko) | 2023-11-30 |
| AU2022246842A9 (en) | 2023-11-16 |
| PE20240823A1 (es) | 2024-04-18 |
| EP4313311A1 (en) | 2024-02-07 |
| DOP2023000207A (es) | 2024-01-15 |
| CA3213682A1 (en) | 2022-10-06 |
| CN118165109A (zh) | 2024-06-11 |
| CN117177994A (zh) | 2023-12-05 |
| IL305600A (en) | 2023-11-01 |
| AU2022246842A1 (en) | 2023-11-02 |
| MX2023011662A (es) | 2023-10-11 |
| US20220363761A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500642A1 (en) | Anti-garp antibody | |
| BR112019010943A8 (pt) | Usos de um anticorpo que se liga especificamente ao domínio extracelular de tigit humano para a inibição do crescimento do tumor, composição que compreende o dito anticorpo, polinucleotídeo, vetor e célula | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| PH12019501014A1 (en) | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof | |
| EA201890443A1 (ru) | Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение | |
| BR112018011029A2 (pt) | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits | |
| NZ737726A (en) | Multispecific antigen-binding molecules and uses thereof | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| TN2016000046A1 (en) | Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof | |
| PH12016500291B1 (en) | Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof | |
| BR112018003782A2 (pt) | composições e métodos para o tratamento da dor | |
| BR112012012918A8 (pt) | Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes | |
| EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
| MX2016004285A (es) | Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma. | |
| MX2019000428A (es) | Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori. | |
| BR112022021641A2 (pt) | Tratamento de combinação de anticorpos anti-cd40 para câncer | |
| MX2020006155A (es) | Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades. | |
| AR125259A1 (es) | Unidades de unión multiespecíficas que comprenden dominios de unión a pd-1 | |
| MX2020003806A (es) | Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. | |
| CL2023002930A1 (es) | Dominios de unión a pd-1 novedosos | |
| MX2020008768A (es) | Agentes anticuerpos anti-cd25. | |
| BR112016014882A2 (pt) | Anticorpos monoclonais e processo para produção dos mesmos, composições, usos dos referidos anticorpos e composições, hibridoma murino i-4686, ácido nucleico isolado, vetor, e célula hospedeira | |
| BR112019011370A2 (pt) | terapia de combinação | |
| BR112022002761A2 (pt) | Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40 | |
| MX2022015475A (es) | Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma. |